TMCI Stock Forecast: Treace Medical Concepts, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering Treace Medical Concepts, Inc. hold a median 12-month price target of $6.5 — +50.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 55 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Treace Medical Concepts, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (85): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (16): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
TMCI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TMCI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +50.8% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Nov 2026 | Stifel | Upgrade | Buy | $4.50 → $6.50 |
| 10 Aug 2026 | Truist Securities | Maintains | Hold | $4.00 → $5.00 |
| 16 July 2026 | Truist Securities | Maintains | Hold | $2.00 → $4.00 |
| 2 Mar 2026 | Lake Street | Maintains | Buy | — |
| 7 Jan 2026 | Stifel | Maintains | Hold | — |
| 18 Dec 2025 | Truist Securities | Maintains | Hold | — |
| 10 Nov 2025 | Truist Securities | Reiterates | Hold | — |
| 7 Nov 2025 | BTIG | Downgrade | Neutral | — |
| 7 Nov 2025 | JP Morgan | Downgrade | Underweight | — |
| 7 Nov 2025 | UBS | Maintains | Neutral | — |
| 15 Oct 2025 | Truist Securities | Maintains | Hold | — |
| 4 Sept 2025 | Truist Securities | Maintains | Hold | — |
| 8 Aug 2025 | Stifel | Maintains | Hold | — |
| 8 Aug 2025 | UBS | Maintains | Neutral | — |
| 9 May 2025 | UBS | Maintains | Neutral | — |
| 11 Apr 2025 | Truist Securities | Maintains | Hold | — |
| 13 Mar 2025 | Truist Securities | Maintains | Hold | — |
| 3 Mar 2025 | Truist Securities | Maintains | Hold | — |
| 31 Dec 2024 | Lake Street | Initiates | Buy | — |
| 18 Dec 2024 | Truist Securities | Maintains | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TMCI.
This page is one stock. Monday covers all of them.
TMCI appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
TMCI vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Treace Medical Concepts, Inc. returned +65.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
TMCI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 1.4×
- Price / book
- 4.6×
- EV / EBITDA
- —
Cheaper than 58% of US stocks
Cheaper than 20% of US stocks
- Revenue growth (YoY)
- −3.9%
- Earnings growth (YoY)
- —
- Gross margin
- 78.5%
- Operating margin
- −24.4%
- Net margin
- −27.4%
Higher than 22% of US stocks
Higher than 90% of US stocks
Higher than 22% of US stocks
Higher than 14% of US stocks
- Return on equity
- −74.0%
- Return on assets
- −16.5%
- Dividend yield
- —
Higher than 17% of US stocks
Higher than 22% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Treace Medical Concepts, Inc. has a market value of $282.6M and an enterprise value of $317.6M.
Revenue in the twelve months to 30 June 2026: $205.3M. The latest quarter shrank 4.2% year on year.
Net income over the same four quarters: −$59.5M, a −29.0% net margin.
Diluted earnings per share, trailing twelve months: −$0.93.
Free cash flow in the twelve months to 30 June 2026: −$25.0M.
Treace Medical Concepts, Inc. employs 450 people — $456K of revenue per employee.
Data provided by Twelve Data
TMCI and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at TMCI’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Treace Medical Concepts, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about TMCI
What is the TMCI stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Treace Medical Concepts, Inc. have a median 12-month price target of $6.5, with estimates ranging from $5 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is TMCI stock a buy right now?
Of the 5 analysts covering Treace Medical Concepts, Inc., 2 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Treace Medical Concepts, Inc. 55 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank TMCI?
As at 21 Nov 2026, Treace Medical Concepts, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (85 of 100).
Will TMCI stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +50.8% from the last close, and Ticker Nerd's factor model ranks Treace Medical Concepts, Inc. 55 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the TMCI stock forecast for 2030?
No analyst covering Treace Medical Concepts, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TMCI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $7 over the next 12 months.
How has TMCI stock performed over the past year?
Treace Medical Concepts, Inc. returned +65.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Treace Medical Concepts, Inc. do?
Treace Medical Concepts Inc. is a medical technology company focused on orthopedic solutions for foot and ankle care. Its core offerings include surgical systems, instruments, implants, and biologic solutions designed for the treatment of bunion deformities and related midfoot conditions.
About Treace Medical Concepts, Inc.
Treace Medical Concepts Inc. is a medical technology company focused on orthopedic solutions for foot and ankle care. Its core offerings include surgical systems, instruments, implants, and biologic solutions designed for the treatment of bunion deformities and related midfoot conditions. The company’s product portfolio is centered on procedures that help surgeons address the underlying structure of hallux valgus, with systems such as Lapiplasty supporting three-dimensional bunion correction. Treace Medical Concepts serves orthopedic surgeons, podiatrists, ambulatory surgery centers, and other healthcare providers involved in foot and ankle surgery. Its products are used in commercial-stage clinical settings and are part of the broader medical devices market, where the company contributes specialized tools intended to improve procedural consistency and surgical workflow. Headquartered in Ponte Vedra Beach, Florida, Treace Medical Concepts operates as a focused player in the musculoskeletal device segment, with an emphasis on dedicated treatment solutions for bunion and midfoot procedures.
CEO Mr. John T. Treace · 450 employees · United States · https://www.treace.com